Primary sclerosing cholangitis is a long-term disease that scars and narrows the bile ducts in and around the liver. People with primary sclerosing cholangitis often feel tired and itchy, and some notice yellowing of the skin or eyes. It tends to progress over years, and many living with primary sclerosing cholangitis are diagnosed in early to mid-adulthood. Treatment focuses on managing symptoms, preventing infections, and monitoring for complications, and some eventually need a liver transplant. The outlook varies, but many people live for years with regular care and follow-up.
Overview
Primary sclerosing cholangitisSymptoms
Primary sclerosing cholangitis often causes no early symptoms. When symptoms appear, people may notice tiredness, itchy skin, right‑upper belly discomfort, dark urine, pale stools, or jaundice. Fevers and chills can occur during bile duct infections.
Outlook and prognosis
Many people with primary sclerosing cholangitis stay stable for years, with care focused on easing symptoms and protecting the liver. Over time, scarring can progress and raise risks like bile duct infections, cirrhosis, and bile duct cancer. Regular monitoring, timely treatment of infections or blockages, and consideration of transplant when needed help people live longer, fuller lives.
Causes and risk factors
Primary sclerosing cholangitis likely stems from immune dysregulation in genetically susceptible people. Risk rises with inflammatory bowel disease (especially ulcerative colitis), male sex, and family history; certain HLA genes contribute. Environmental influences are unclear; smoking and infections show inconsistent links.
Genetic influences
Genetics play a moderate role in primary sclerosing cholangitis. Having certain gene variants or a family history raises risk, but most cases have no clear inherited pattern. PSC likely arises from a mix of genes, immune factors, and environment.
Diagnosis
The diagnosis of Primary sclerosing cholangitis uses liver blood tests and specialized MRI of the bile ducts (MRCP) showing typical narrowings. Doctors also rule out other causes; occasionally endoscopic imaging or a liver biopsy is needed.
Treatment and drugs
Primary sclerosing cholangitis care focuses on easing symptoms, protecting the bile ducts and liver, and watching for complications. Doctors may use bile‑acid medicines, vitamin support, antibiotics for infections, endoscopic dilation or stents, and, when needed, liver transplant. Regular checkups track liver health and cancer risk.
Symptoms
Many people feel well for a long time, with no obvious problems. Early symptoms of primary sclerosing cholangitis can be vague—tiredness, itchy skin, or bouts of right-sided belly discomfort. As it progresses, yellowing of the eyes or skin, darker urine, paler stools, and on-and-off fevers from bile duct infections may show up. Symptoms vary from person to person and can change over time.
Many people with primary sclerosing cholangitis have no symptoms for years. Subtle issues like mild fatigue or itch may be the first clues. Routine blood tests or scans sometimes spot liver changes before you feel them.
A deep, persistent tiredness is common in primary sclerosing cholangitis. It may not improve with rest and can make work, school, or exercise feel harder. Energy can dip more by late afternoon.
Itchy skin, often worse at night, is common when bile backs up. It can affect your arms, legs, palms, or the whole body. Scratching can break the skin and disturb sleep.
Yellow eyes or skin can appear as bile builds up in primary sclerosing cholangitis. Loved ones often notice the changes first. It may come and go or slowly increase over time.
How people usually first notice Primary sclerosing cholangitis?
Many people first notice primary sclerosing cholangitis when routine blood tests show abnormal liver enzymes, often before any symptoms. When symptoms do appear, early clues can include persistent fatigue, itchy skin, or brief episodes of jaundice (yellowing of the eyes/skin), sometimes alongside right‑upper abdominal discomfort. Because PSC commonly occurs in people with inflammatory bowel disease, some are flagged during checkups for colitis, making these early lab changes and subtle symptoms the first signs of primary sclerosing cholangitis.
Types of Primary sclerosing cholangitis
Primary sclerosing cholangitis (PSC) doesn’t look exactly the same for everyone, and doctors recognize a few well-established variants that help explain different symptom patterns and outcomes. These variants are based on where the bile duct scarring occurs, how it shows up on imaging, and whether another autoimmune condition overlaps. People may notice different sets of symptoms depending on their situation. Knowing the main types of PSC can help you and your care team understand what to expect and which tests or treatments may fit best when discussing types of PSC.
Classic large-duct PSC
Scarring affects the larger bile ducts inside and outside the liver. Many live with fatigue and itch, and some develop jaundice over time.
Small-duct PSC
Inflammation is limited to tiny bile ducts in the liver and imaging can look normal. Symptoms can be milder, but blood tests suggest cholestasis and biopsy confirms the diagnosis.
PSC–IBD overlap
PSC occurs alongside inflammatory bowel disease, usually ulcerative colitis. Diarrhea, abdominal cramping, and rectal bleeding can sit alongside fatigue and itch from PSC.
Overlap with autoimmune hepatitis
Features of autoimmune hepatitis appear with PSC, sometimes called PSC-AIH overlap. People may have higher liver enzymes and respond partly to immune-suppressing medicines.
IgG4-related sclerosing cholangitis
Bile duct inflammation is part of IgG4-related disease and can mimic PSC. Pancreas or salivary gland involvement and high IgG4 blood levels often guide diagnosis.
What genetics can tell you about symptoms
Some people with certain HLA variants (like HLA-B8 or DRB1*03/DR3) are more likely to develop PSC and often have itching, fatigue, and jaundice alongside inflammatory bowel disease. Variants in genes affecting bile transport (such as ABCB4) can worsen bile duct scarring, leading to cholangitis flares and vitamin deficiencies.
Causes and risk factors
The exact cause of primary sclerosing cholangitis is unknown, and the immune system likely plays a key role. Risk is higher with inflammatory bowel disease, especially ulcerative colitis, and it is more common in men and in people of Northern European ancestry. Family history and certain immune-related genes can raise risk, but this does not predict early symptoms of primary sclerosing cholangitis. Doctors distinguish between risk factors you can change and those you can’t. Changes in gut bacteria, past infections, and other environmental triggers are being studied, and there are no clear lifestyle risks yet.
Environmental and biological risk factors
Understanding what raises risk can make day-to-day decisions feel a little clearer when you’re worried about your liver and digestion. Awareness of both biological and environmental influences helps you feel prepared. For primary sclerosing cholangitis, several body-based factors and a few outside influences have been linked with higher likelihood. Knowing these can also help you notice early symptoms of primary sclerosing cholangitis and seek care sooner.
People with ulcerative colitis or Crohn’s colitis have a higher chance of developing primary sclerosing cholangitis. Ongoing gut inflammation may signal the immune system in ways that affect the bile ducts. Shared immune pathways likely connect the two conditions.
Men are diagnosed with primary sclerosing cholangitis more often than women. Differences in hormones and immune responses may contribute. This pattern is seen across multiple countries.
Diagnosis most often occurs in people in their 30s or 40s. While it can happen at any age, this window shows the highest risk. Children and older adults can still develop primary sclerosing cholangitis, but less commonly.
Thyroid disease, type 1 diabetes, and other immune conditions tend to co-occur. Having another immune-mediated condition is linked with higher odds of primary sclerosing cholangitis. This points to an immune system that is more reactive.
Genetic risk factors
Primary sclerosing cholangitis (PSC) has a strong genetic component, driven by many small DNA changes rather than a single gene. Genetic background does not predict early symptoms of Primary sclerosing cholangitis, but it can raise a person’s chance of developing it. Carrying a genetic change doesn’t guarantee the condition will appear. Research points to immune system genes, especially in the HLA region, and several non-HLA genes that tune inflammation and bile duct defenses.
Family history: Having a parent, sibling, or child with PSC raises your chance of developing the condition compared with the general population. This pattern supports a hereditary component, though the exact genes vary between families.
HLA region types: Certain immune-system HLA types are strongly associated with Primary sclerosing cholangitis. These inherited markers influence how the immune system recognizes proteins in the bile ducts.
Immune signaling genes: Variants in genes that tune inflammation and immune cell activity add small, additive increases in PSC risk. Each change by itself does little, but together they can shift susceptibility.
IBD-related genetics: Several risk regions are shared between PSC and ulcerative colitis or Crohn’s disease. Carrying these overlapping variants raises PSC susceptibility even if bowel symptoms never appear.
Ancestry background: PSC is more common in people of Northern European ancestry, reflecting population differences in risk variants. Rates in other groups vary, and studies are ongoing to map ancestry-specific risk.
Polygenic pattern: PSC risk comes from many common DNA changes rather than a single faulty gene. This is why routine clinical genetic testing cannot yet predict who will develop PSC.
Lifestyle risk factors
Primary sclerosing cholangitis isn’t caused by lifestyle, but daily habits can influence symptoms, liver stress, and complications over time. Diet and activity choices can affect fatigue, nutrition, bone health, and the risk of fluid buildup or overlapping fatty liver disease. This section covers lifestyle risk factors for Primary sclerosing cholangitis and practical ways they relate to disease course.
Alcohol adds extra strain to cholestatic and scarred liver tissue, increasing the risk of inflammation and decompensation. Even modest drinking can worsen progression or complications, so many people with PSC are advised to limit or avoid alcohol.
Low physical activity contributes to muscle loss and fatigue common in PSC. Regular movement helps maintain strength, supports mood, and lowers overlap with fatty liver that can speed fibrosis.
Inadequate protein and calories can worsen fatigue and sarcopenia seen with chronic cholestasis. Unbalanced diets may also aggravate fat-soluble vitamin deficiencies that are more likely in PSC.
Excess salt promotes fluid retention, swelling, and ascites when PSC advances toward cirrhosis. Lower-sodium choices can lessen these complications and reduce diuretic needs.
Risk prevention
Primary sclerosing cholangitis (PSC) isn’t fully preventable because the exact cause isn’t known. Prevention is about lowering risk, not eliminating it completely. For many, the focus is on protecting the liver, catching problems early, and reducing infections or cancers linked with PSC. Regular care with a liver specialist can make a real difference over time.
Routine liver blood tests and imaging can catch changes before they cause major trouble. Share new concerns, including early symptoms of primary sclerosing cholangitis like itching or deep fatigue. Keeping a log of symptoms helps your team spot patterns.
Stay up to date on hepatitis A and B vaccines to shield an already stressed liver. Annual flu and other recommended shots reduce infection risk that can lead to cholangitis.
Avoid or keep alcohol to a minimum to reduce liver strain. If you choose to drink, discuss safe limits with your clinician based on your liver tests.
Check all medicines and supplements with your care team. Some drugs can stress the liver or bile ducts; safer alternatives may be available.
Transmission
Primary sclerosing cholangitis is not contagious, so it cannot be transferred from one person to another. It does not spread through everyday contact, sex, pregnancy, breastfeeding, food or water, or blood exposure.
On the genetics side, there is no simple genetic transmission of Primary sclerosing cholangitis; having a close relative may slightly raise risk, but most people with PSC have no family history. In short, how Primary sclerosing cholangitis is inherited isn’t straightforward, because it likely reflects a mix of immune factors and multiple genes rather than a direct parent‑to‑child pattern.
When to test your genes
Consider genetic testing if you have PSC with a strong family history of inflammatory bowel disease or cholestatic liver disease, or if symptoms started unusually early. Testing may also help when liver findings are unclear, to rule out inherited cholestasis or overlap conditions that change management. Always discuss benefits, limits, and insurance implications with a genetics-trained clinician.
Diagnosis
For many, the first hints are day-to-day issues like stubborn itch, tiredness, or bouts of belly discomfort that don’t add up. Doctors usually begin with simple blood tests and an exam, then use imaging to look at the bile ducts more closely. The diagnosis of Primary sclerosing cholangitis often rests on a typical pattern on specialized MRI scans together with lab results and ruling out look-alike conditions. Some diagnoses are clear after a single visit, while others take more time.
Your clinician asks about itching, fatigue, abdominal pain, and past gut issues such as colitis. They examine your skin, eyes, and belly for signs of bile flow problems.
Cholestatic patterns such as raised alkaline phosphatase and gamma‑GT suggest blocked bile flow. Bilirubin and liver enzymes help gauge severity and guide next steps.
An ultrasound checks liver size and texture and looks for visible bile duct blockage like stones. It helps rule out common mechanical causes before more specific tests.
Magnetic resonance cholangiopancreatography (MRCP) is the preferred noninvasive test to map the bile ducts. Doctors look for multiple narrowings and areas of widening that fit PSC.
Stages of Primary sclerosing cholangitis
Primary sclerosing cholangitis does not have defined progression stages. The condition can move forward at different speeds, with stretches of stability and occasional flare-ups, and changes are usually seen on blood tests and imaging rather than in clear step-by-step symptoms. Early symptoms of primary sclerosing cholangitis can be subtle—like fatigue or itch—so care teams often rely on blood work, MRI-style scans of the bile ducts, and sometimes specialized ultrasound to monitor liver stiffness. Different tests may be suggested to help track bile duct narrowing and liver scarring over time.
Outlook and prognosis
Daily life with primary sclerosing cholangitis (PSC) can be unpredictable—good weeks followed by stretches of fatigue, itch, or belly discomfort. Many people ask, “What does this mean for my future?”, and the answer depends on how quickly bile duct scarring progresses and whether complications develop. Doctors call this the prognosis—a medical word for likely outcomes. Some people experience long quiet periods with minimal symptoms; others notice repeated flares, infections of the bile ducts, or jaundice. Early care can make a real difference, especially when teams watch for early symptoms of primary sclerosing cholangitis like fatigue, itching, and dark urine and treat issues before they snowball.
Looking at the long-term picture can be helpful. Over years to decades, PSC can lead to cirrhosis, portal hypertension, and eventually liver failure for some, making liver transplant the main life-extending treatment when the liver can’t keep up. With ongoing care, many people maintain stable health for a long time, but risks are not zero: bile duct cancer (cholangiocarcinoma) occurs in a small percentage, and the risk is higher soon after diagnosis; gallbladder growths and colon cancer risk also increase, especially when PSC occurs with inflammatory bowel disease. Survival varies widely—many live 10–20 years or more from diagnosis, while others progress faster—because disease speed, infections, associated bowel disease, and access to timely transplant all matter. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, plus how soon complications are recognized and managed.
Talk with your doctor about what your personal outlook might look like. Regular follow-up, vaccination, managing itch and vitamin deficiencies, screening for bile duct and colon cancers, and prompt treatment of infections can lower complications and improve quality of life. If PSC advances, early referral to a transplant center helps with planning and, when needed, listing—outcomes after transplant are generally good, with most people returning to active routines.
Long-term effects
Primary sclerosing cholangitis can change slowly over years, and for many the day-to-day impact centers on energy, itch, and digestive comfort. Long-term effects vary widely, and no two people follow exactly the same path. Even if early symptoms of primary sclerosing cholangitis are mild, deeper scarring in the bile ducts can build over time. Over the years, the course may stay stable for a while or move toward cirrhosis, infections, and cancers linked to the bile ducts or bowel.
Narrowed bile ducts can slowly damage the liver. This can lead to cirrhosis and eventually liver failure.
Rising pressure in the liver can cause a swollen spleen and enlarged veins in the esophagus or stomach. Some develop fluid buildup in the belly (ascites).
Recurrent infections (cholangitis) can occur in primary sclerosing cholangitis. These episodes may bring fever, chills, worsening jaundice, and hospital stays.
Tight spots in the main bile ducts can trigger sudden jaundice and dark urine. Stools may turn pale, and itching can intensify.
How is it to live with Primary sclerosing cholangitis?
Living with primary sclerosing cholangitis can feel unpredictable: some days bring crushing fatigue or itch that steals sleep, while other days are quieter but framed by regular labs, imaging, and check-ins to watch the liver and bile ducts. For many, planning daily life means pacing energy, avoiding alcohol, staying up to date on vaccines, and being mindful of gut symptoms, since PSC often travels alongside inflammatory bowel disease. Friends and family may notice shifts in energy and mood, help with appointments or meals during flare-ups, and learn to spot signs that need prompt care—worsening jaundice, fevers, or new belly pain. Over time, people often build steady routines, lean on care teams and peer support, and balance vigilance with a full life, even as they prepare for possibilities like cholangitis episodes or, in some, evaluation for liver transplant.
Treatment and drugs
Primary sclerosing cholangitis is managed with a mix of symptom relief, protecting the liver, and planning for complications, since no medicine has been proven to stop the disease. Doctors may use bile acid medicines to ease itching, treat infections of the bile ducts with antibiotics, and perform endoscopic procedures to open tight bile duct narrowings and improve drainage. Regular monitoring includes blood tests, imaging, and colonoscopy for those with ulcerative colitis, plus screening for bile duct and colon cancers; vaccination against hepatitis A and B, bone health support, and nutrition counseling are also common parts of care. When cirrhosis or repeated infections develop, liver transplant is the only treatment that can replace the damaged bile ducts, and outcomes after transplant are generally good. Finding the right therapy can take some time, so keep track of how you feel, and share this with your care team.
Non-drug treatment
Living with Primary sclerosing cholangitis (PSC) often means balancing energy, digestion, and skin comfort day to day. Non-drug treatments often lay the foundation for feeling better, while medical and procedural care address flares or complications. Practical steps can support nutrition, ease itching, protect bones, and lower infection risks. Regular monitoring also helps catch early symptoms of Primary sclerosing cholangitis and complications sooner.
People living with Primary sclerosing cholangitis may need extra calories and protein when appetite is low or weight drops. A dietitian can tailor meals and plan support for fat‑soluble vitamins if levels are low.
Keep skin cool and well moisturized, wear loose cotton, and take short, lukewarm showers. Oatmeal or menthol lotions and trimming nails can lower scratching and protect the skin.
Stay up to date on hepatitis A and B vaccines and routine immunizations to reduce infection risks. Your care team can help with timing around procedures or illness.
Avoid or limit alcohol to reduce extra strain on the liver. If cutting back is hard, brief counseling or support groups can help you stay on track.
Your genes may have an impact on how drugs work for you
Medicines used for primary sclerosing cholangitis can work differently based on your genes, which influence how quickly your liver processes drugs and how strongly your immune system responds. Pharmacogenetic testing may guide dosing or drug choice, helping reduce side effects and improve benefit.
Pharmacological treatments
For primary sclerosing cholangitis (PSC), medicines mainly ease symptoms and manage complications; none have been proven to stop or reverse the disease. Treatment is tailored to what bothers you most—itching, infections, vitamin shortages, or bone health. Not everyone responds to the same medication in the same way. Your care team will also watch for other conditions that often travel with PSC, like inflammatory bowel disease, and adjust medicines as needed.
Ursodiol may improve liver blood tests in primary sclerosing cholangitis but has not clearly changed long-term outcomes. Moderate doses are preferred, as high doses may be harmful.
Cholestyramine or colesevelam can reduce PSC-related itching by trapping bile acids in the gut. Take them away from other pills to avoid blocking absorption.
Rifampin can ease severe itching when resins don’t help, including early symptoms of primary sclerosing cholangitis like persistent pruritus. Doctors monitor for liver side effects and drug interactions.
Naltrexone (an opioid blocker) may reduce refractory itching in PSC. It should be avoided with opioid pain medicines and is usually started at a low dose.
Genetic influences
Genes seem to influence who develops primary sclerosing cholangitis (PSC), but they don’t act alone. Family history is one of the strongest clues to a genetic influence. Having a close relative with PSC raises your risk compared with the general population, yet the overall chance is still low, and it isn’t passed down in a simple yes-or-no way. Research points to many immune-system gene regions working together—like several dimmer switches that tweak how the body responds—while environmental factors and the gut microbiome add to the mix. PSC often occurs alongside ulcerative colitis, and some of the same immune pathways appear to link the two. Because of this complex picture, routine genetic testing cannot diagnose PSC or predict with certainty who will develop it. If you’re wondering whether primary sclerosing cholangitis is hereditary in your family, talking with your care team about your family history can help them decide whether any follow-up is useful.
Is Primary sclerosing cholangitis genetic?
Genetics play a moderate role in primary sclerosing cholangitis. Having certain gene variants or a family history raises risk, but most cases have no clear inherited pattern. PSC likely arises from a mix of genes, immune factors, and environment.
Pharmacogenetics—how genetics influence drug effects
In primary sclerosing cholangitis (PSC), genes don’t yet point to a single proven medication, but they can influence how you process some of the drugs used in care. Many people with PSC also live with inflammatory bowel disease; when thiopurines such as azathioprine or 6-mercaptopurine are used, checking TPMT and NUDT15 can guide dosing and lower the risk of severe low white blood cells. Because cholestasis can slow the liver’s handling of medicines, both your genetic makeup and your current liver function matter when using options like rifampin for itching or antibiotics for infection. Alongside medical history and liver tests, genetic testing may help tailor choices or doses for certain drugs. Pharmacogenetic testing in primary sclerosing cholangitis is most useful when a medicine already has strong gene–drug guidance, and it isn’t a routine test for PSC itself. Your care plan also weighs other factors such as drug interactions, lab trends, and how you feel from day to day.
Interactions with other conditions
Living with primary sclerosing cholangitis (PSC) often goes hand in hand with inflammatory bowel disease, especially ulcerative colitis, and the two don’t always flare at the same time. Doctors call it a “comorbidity” when two conditions occur together. When PSC and IBD travel together, the long‑term risk of colon cancer is higher, so colonoscopies are usually started earlier and done more often than usual. Some people also have overlap with autoimmune hepatitis or other immune‑related conditions, which can boost inflammation in the liver and make jaundice or itching worse during a flare. Infections in the bile ducts can occur more easily in PSC, and other illnesses—or even a blocked stone or a procedure—may tip someone into fever, chills, and right‑upper‑belly pain. As PSC progresses, it can interact with conditions linked to advanced liver disease, such as bone thinning (osteoporosis) or fluid build‑up, and the risk of cancers of the bile ducts or gallbladder rises, which changes screening plans even if early symptoms of Primary sclerosing cholangitis are mild or absent.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described long-lasting jaundice, itching, and bouts of fever after meals—patterns that today sound like biliary disease. Families and communities once noticed patterns of lingering “gall complaints” that didn’t fit simple gallstones, especially in younger adults who otherwise seemed healthy.
First described in the medical literature as a scarring disease of the bile ducts in the early 20th century, primary sclerosing cholangitis emerged from careful autopsy reports and surgical notes. Early physicians saw narrowed, beaded ducts and unexplained liver damage. Initially understood only through symptoms, later imaging studies like ERCP and then MRCP helped clinicians see the characteristic strictures during life, not just after. Liver biopsy techniques and cholangiography added detail, showing inflammation alongside fibrous rings that made the ducts behave like kinked tubes.
With each decade, researchers recognized how often primary sclerosing cholangitis travels with inflammatory bowel disease, especially ulcerative colitis. This connection shifted thinking from a purely mechanical blockage to immune-related pathways. As organ transplantation became safer in the 1980s and 1990s, outcomes for advanced disease improved, and transplant registries helped map its course over time. Once considered rare, now recognized as more common in certain groups, PSC was seen more frequently in Northern Europe and North America, though it occurs worldwide.
Advances in genetics and immunology added more pieces. Instead of a single “PSC gene,” studies pointed to several immune-related genes that may raise risk, while infections and the gut–liver axis remained part of the discussion. Over time, descriptions became more precise: large-duct versus small-duct forms, overlap with autoimmune hepatitis in some, and a clearer picture of cancer risks involving the bile ducts and gallbladder. These distinctions matter because early symptoms of primary sclerosing cholangitis can be quiet or vague, and many people are diagnosed only after routine blood tests or imaging.
Current studies build on a long tradition of observation, moving from descriptive case series to large cohorts and international collaborations. Noninvasive tools—like MRI-based imaging and serum markers—are being refined to track disease without frequent procedures. At the same time, researchers are testing medicines that target bile acids, immunity, and microbes in the gut to slow scarring and reduce complications. Not every early description was complete, yet together they built the foundation of today’s knowledge.
Looking back helps explain why PSC care focuses on timely surveillance, managing symptoms such as itching and fatigue, and coordinating liver and colon care for those living with both PSC and inflammatory bowel disease. The story of primary sclerosing cholangitis continues to evolve, shaped by careful observation, improving technology, and people who share their experiences to guide better care.